Skip to content
Cogent Biosciences
  • Purpose
  • Programs
  • People
  • Investors & Media
    • Company Profile
    • Press Releases
    • Events
    • Presentations
    • Posters & Publications
    • Analyst Coverage
    • Corporate Goverance
      • DOCUMENTS & CHARTERS
      • MANAGEMENT
      • BOARD OF DIRECTORS
      • COMMITTEE COMPOSITION
    • SEC Filings
    • Investor Resources
      • FAQS
      • CONTACT US
  • Search

Real Challenges,

Real Solutions

Precision therapies for genetically defined diseases.

Opportunity for Impact

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.

Millions of people around the world are living with a genetically defined disease. Mutations can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases. For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.

Learn More

Advancing Best-in-Class Precision Therapies

At Cogent, we start with the end in mind – with the goal of delivering meaningful therapies that improve human health. We focus on diseases where the cause is well understood and is directly linked to a genetic mutation, providing a path forward to develop novel precision therapies. Our lead therapeutic (PLX9486) is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying PLX9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.

Learn More

Our People,
Our Promise.

Cogent is driven by the patients we serve and committed to the opportunity to deliver novel precision therapies to patients with unmet medical needs. We are a Company of people who are passionate and dedicated to turning the promises of our therapies into reality in order to transform the lives of patients.

Learn More
Learn More

Latest News

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Sto…

Total gross proceeds from the offering to Cogent are approximately $115.0 million CAMBRIDGE, Mass. , Dec. 4, 2020 /PRNewswire/…

read more

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of …

CAMBRIDGE, Mass. , Dec. 1, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Commo…

CAMBRIDGE, Mass. , Nov. 30, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer

Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice…

read more

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtu…

CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ —  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Ad…

Majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and…

read more

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Con…

CAMBRIDGE, Mass. , Nov. 12, 2020 /PRNewswire/ —  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides …

Andrew Robbins appointed President, CEO and Director   Final results from PLX9486 + sunitinib Phase 1/2 study in GIST…

read more

Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare…

CAMBRIDGE, Mass. , Nov. 5, 2020 /PRNewswire/ —  Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing…

read more

Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer

Seasoned executive with deep experience developing precision medicines for genetically defined diseases, most recently as COO of Array Biopharma…

read more

Cogent Biosciences, Inc.

© Copyright 2021 Cogent Biosciences, Inc.

Contact Us

Legal

Privacy Policy